Molecule to Market: Inside the outsourcing space Raman Sehgal

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with J.D. Mowery, President and Chief Executive Officer at KBI Biopharma.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with J.D., covering:
The experience of bringing a product to market... and then many years later seeing that product used on his wife to help bring his sons into the world
How bringing a commercial facility online for Genentech to impact thousands of patients compares to the ‘vain to vain’, hospital-based, one-off patient CAR-T product for Juno
Why the ethos of taking care of the person on your left and the person on your right helps with the scale-up of a multi-national global CDMO
The emergence of a partnership-based, absorption business model between innovators and CDMOs in the wake of the shift in capital markets
What the next generation CDMO will look like…
J.D. is an accomplished leader with a distinguished reputation in the biopharma industry and proven expertise in guiding global innovators and contract development and manufacturing organizations (CDMOs) for nearly 25 years.
Throughout his diverse career, J.D. has demonstrated strategic vision and the ability to drive all aspects of an organization, including operations, R&D, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. He is an expert in diverse modalities, including small molecules, biologics, and cell and gene therapy. J.D. has held executive leadership positions as 
Head of Operations at Lonza and Executive Vice President of U.S. Operations at AGC Biologics. He has also held influential roles at innovators, including Genentech, Celgene, and Juno, and most recently served as Chief Operating Officer at Treadwell Therapeutics. J.D. holds a Bachelor of Science from George Fox University and an MBA from Marylhurst University.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering:
The fast, easy, scalable, precise, and non-patent-protected benefits of micronization
How a synergistic capability alliance led to the eventual sale of his business to Lonza Capsugel
The risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a team
How a ‘getting the band back together’ call led to TJ taking back the site he once sold to create Microsize
The importance of strategic partnerships and recognizing that you can’t do everything yourself
TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.
 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering:
How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseases
Having the DNA of an entrepreneur but taking the time to gain a big pharma foundation
The harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology company
The need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successes
Howard co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO
He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines.
Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pamela Bush, Chief Business Officer at Predictive Oncology.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pam, covering:
The key aspects to successful deal-making learned over a decade with Eli Lily
How a passion for curing cancer led Pamela to an opportunity to impact thousands of promising candidates directly
How active machine learning is being used to screen molecules, help companies fail fast, and increase the success of a molecule in clinical trials
The challenge of selling a disruptive, game-changing platform that could become a vital decision tool in the future
Pamela Bush, Ph.D. has over twenty years of experience in venture creation, finance, and business development in the life sciences industry. Pamela is the Chief Business Officer for Predictive Oncology where she leads the strategy and business development activities across the portfolio. Prior to joining Predictive Oncology, Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 100+ life sciences start-ups. Pamela holds a Ph.D. in Molecular Genetics and an MBA from Carnegie Mellon University.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tushar Misra, Chief Manufacturing Officer at Mersana Therapeutics.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tushar covering:
How his opportunistic nature led him to several roles, companies and locations across the processing and biopharmaceutical sector
Being given the task of building a worldwide manufacturing and supply chain infrastructure for the commercial launch of a biologic oncology product globally for Takeda
Key components of a strong CDMO partnership ‘beyond checking boxes’ and how the type of product impacts the selection process
The harsh realities of a recent clinical failure for a biopharmaceutical company that impacts employees and patients
How the explosion of modalities have driven growth across all segments the outsourcing space
Tushar Misra is the Chief Manufacturing Officer at Mersana Therapeutics, a biopharmaceutical company specializing in the discovery and development a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. He has over 30 years of experience in developing drugs that involve small and large molecules and ADCs, as well as the development and management of worldwide commercial supply chains.
Prior to Mersana, Tushar was EVP, Head of Technical Development & Manufacturing at Laronde, where he led the process development and manufacturing team for end-to-end manufacturing for RNA products. In addition, Tushar worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
 

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mike Martin, Chief Executive Officer at CAI.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering:
How a passion for engineering led to a lifetime in life sciences - including 32 years with Eli Lilly
Why working in China, Puerto Rico, and Ireland and the exposure to new cultures changed this ‘mid-west farm boy’s view of the world
A very short attempt at retirement... and what tempted Mike back into the working world
Lessons learned from years of being the client, but also knowing when to dial down the client voice as a service provider
As the CEO of CAI, Mike Martin guides a team of 800+ across the US, Europe, and APAC for the global professional services firm focused on engineering and quality consulting.
With over 30 years in the pharmaceutical industry, including decades at Eli Lilly, Mike has experience in engineering, operational leadership, engineering leadership, and large-scale project management in diverse global settings, specifically major capital projects in the US, Puerto Rico, China, and Ireland.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.